-$0.19 Earnings Per Share Expected for MediWound Ltd. (MDWD) This Quarter
Wall Street brokerages expect MediWound Ltd. (NASDAQ:MDWD) to announce earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for MediWound’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.20). MediWound posted earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year-over-year growth rate of 26.9%. The firm is expected to issue its next earnings report on Monday, November 13th.
On average, analysts expect that MediWound will report full year earnings of ($0.76) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.70). For the next financial year, analysts anticipate that the firm will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.85) to ($0.48). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow MediWound.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. MediWound’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.34) EPS.
Several brokerages have weighed in on MDWD. Zacks Investment Research cut MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the stock a “buy” rating in a report on Tuesday, October 17th. Jefferies Group LLC set a $10.00 target price on MediWound and gave the stock a “buy” rating in a report on Friday, August 25th. ValuEngine upgraded MediWound from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, Cowen and Company began coverage on MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $9.15.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in shares of MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 8,745 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 1,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of MediWound by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after acquiring an additional 213,745 shares in the last quarter. 19.55% of the stock is owned by hedge funds and other institutional investors.
MediWound (MDWD) opened at 5.00 on Monday. MediWound has a 12-month low of $4.25 and a 12-month high of $8.25. The company’s market cap is $109.77 million. The firm has a 50-day moving average price of $5.37 and a 200-day moving average price of $6.33.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.